{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Syringe&page=4",
    "query": {
      "intervention": "Syringe",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 1364,
    "total_pages": 137,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Syringe&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Syringe&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T15:00:42.870Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02215200",
      "title": "ATG-GCSF in New Onset Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Anti-Thymocyte Globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte colony stimulating factor (GCSF)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for ATG)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for GCSF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 89,
      "start_date": "2014-12",
      "completion_date": "2018-08",
      "has_results": true,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-10-29T15:00:42.870Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Stanford, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02215200"
    },
    {
      "nct_id": "NCT05609812",
      "title": "Atacicept in Subjects With Active Lupus Nephritis (COMPASS)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lupus Nephritis (LN)"
      ],
      "interventions": [
        {
          "name": "Atacicept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-11-02",
      "completion_date": "2028-12-15",
      "has_results": false,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-10-29T15:00:42.870Z",
      "location_count": 26,
      "location_summary": "Huntsville, Alabama • La Jolla, California • La Palma, California + 19 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05609812"
    },
    {
      "nct_id": "NCT00598702",
      "title": "Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain",
        "Fever"
      ],
      "interventions": [
        {
          "name": "IV Acetaminophen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "37 Weeks",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "37 Weeks to 16 Years"
      },
      "enrollment_count": 100,
      "start_date": "2008-01",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-10",
      "last_synced_at": "2026-10-29T15:00:42.870Z",
      "location_count": 14,
      "location_summary": "Stanford, California • Wilmington, Delaware • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00598702"
    },
    {
      "nct_id": "NCT01185288",
      "title": "A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Adalimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 309,
      "start_date": "2010-09",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-03-18",
      "last_synced_at": "2026-10-29T15:00:42.870Z",
      "location_count": 46,
      "location_summary": "Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01185288"
    },
    {
      "nct_id": "NCT01688921",
      "title": "Jet Injection for Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "AFLURIA vaccine (2012-2013 formulation)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Needle-Syringe",
          "type": "DEVICE"
        },
        {
          "name": "Stratis needle-free injection device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "PharmaJet, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 1250,
      "start_date": "2012-10",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2017-11-01",
      "last_synced_at": "2026-10-29T15:00:42.870Z",
      "location_count": 3,
      "location_summary": "Fort Collins, Colorado • Loveland, Colorado",
      "locations": [
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Loveland",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01688921"
    },
    {
      "nct_id": "NCT03389685",
      "title": "Can PRP Reduce Pro-Inflammatory Biomarkers Following ACL Injury",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ACL - Anterior Cruciate Ligament Rupture",
        "ACL Injury"
      ],
      "interventions": [
        {
          "name": "Platelet Rich Plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-09-09",
      "completion_date": "2024-02",
      "has_results": false,
      "last_update_posted_date": "2024-04-15",
      "last_synced_at": "2026-10-29T15:00:42.870Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03389685"
    },
    {
      "nct_id": "NCT02484690",
      "title": "A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 273,
      "start_date": "2015-08-11",
      "completion_date": "2017-09-26",
      "has_results": true,
      "last_update_posted_date": "2020-11-12",
      "last_synced_at": "2026-10-29T15:00:42.870Z",
      "location_count": 52,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02484690"
    },
    {
      "nct_id": "NCT03220113",
      "title": "Treatment of Chronic Migraine Headaches.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Migraine Without Aura, Intractable",
        "Migraine With Typical Aura",
        "Migraine Disorders"
      ],
      "interventions": [
        {
          "name": "Dexamethasone, Lidocaine, Thiamine cohort",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Corona Doctors Medical Clinics, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "10 Years to 90 Years"
      },
      "enrollment_count": 100,
      "start_date": "2017-07-01",
      "completion_date": "2019-07-01",
      "has_results": false,
      "last_update_posted_date": "2018-04-04",
      "last_synced_at": "2026-10-29T15:00:42.870Z",
      "location_count": 1,
      "location_summary": "Corona, California",
      "locations": [
        {
          "city": "Corona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220113"
    },
    {
      "nct_id": "NCT02116803",
      "title": "An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "dovitinib",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2014-05-28",
      "completion_date": "2016-11-28",
      "has_results": true,
      "last_update_posted_date": "2018-03-01",
      "last_synced_at": "2026-10-29T15:00:42.870Z",
      "location_count": 2,
      "location_summary": "Las Vegas, Nevada • The Bronx, New York",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02116803"
    },
    {
      "nct_id": "NCT01737710",
      "title": "Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Fluzone® Intradermal Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone® (Intramuscular) vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 64 Years · Female only"
      },
      "enrollment_count": 368,
      "start_date": "2012-10",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-10-29T15:00:42.870Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Protland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01737710"
    }
  ]
}